Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ralinepag · APD-811

Small molecule · developed by United Therapeutics

Phase 3 Most advanced trial
UTHR Developer
1 Registered trials

What is Ralinepag?

Ralinepag (APD811) is a drug studied in pulmonary arterial hypertension, a condition of high blood pressure in the arteries of the lungs.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
APD-811
Drug type
Small molecule
Therapy area
Cardiovascular, Respiratory
Developer
United Therapeutics (UTHR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
CQY12ZJN6E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03683186 Phase 3 PAH Enrolling by invitation UTHR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiovascular DiseasesConnective Tissue DiseasesFamilial Primary Pulmonary HypertensionHypertensionHypertension, PulmonaryLung DiseasesPAHPulmonary Arterial HypertensionPulmonary HypertensionRespiratory Tract DiseaseVascular Diseases

More from United Therapeutics

Follow UTHR, the company behind Ralinepag

See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UTHR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.